Asset profile

Coramitug

Monoclonal antibody

Phase 3underway

Evidence outlook · registrational

Heart Failure: registrational readout pending

Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2029-06-29.

How the evidence outlook works ↗

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2028 (1)
February 2028 (1)
Phase 2Transthyretin Amyloid Cardiomyopathy (ATTR CM)Active not recruiting
Est. primary completion 2028-02-29 · NCT06260709 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2029 (1)
June 2029 (1)
Phase 3Transthyretin Amyloid Cardiomyopathy (ATTR CM)Recruiting
Est. primary completion 2029-06-29 · NCT07207811 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.